Full Title
Phase 1, Open-label, Multicenter, First-in-human Trial of DS-2243a in Participants with Advanced Solid TumorsPurpose
Researchers want to find the best dose of DS-2243a to use in people with solid tumors. The people in this study have these solid tumors, which have spread beyond their original location:
- Synovial sarcoma
- Myxoid/round cell liposarcoma
- Urothelial cancer
In addition, they have the HLA-A2 protein in their blood. If they have urothelial cancer, their tumors make a protein called NY-ESO.
DS-2243a is a bispecific antibody, which binds to two different proteins. The drug binds to one protein on the surface of cancer cells and one on immune cells. DS-2243a may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy the tumor. It is given as a subcutaneous (under the skin) injection.
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the cancers listed above, which has spread and cannot be treated with standard therapies.
- Have HLA-A2 in your blood and, if you have urothelial cancer, a tumor that makes NY-ESO.
- Have recovered from the serious side effects of prior therapies before getting DS-2243a.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Sandra D’Angelo’s office 646-888-4159.